Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Transcode Therapeutics Inc
(NQ:
RNAZ
)
0.2365
+0.0038 (+1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Transcode Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
May 13, 2024
Via
Benzinga
Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
May 13, 2024
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders.
Via
Benzinga
Squarespace (SQSP) Stock Climbs 13% on $6.9 Billion Deal to Go Private
May 13, 2024
Squarespace stock is up on Monday as SQSP investors react to a $6.9 billion deal to take the business management company private.
Via
InvestorPlace
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
May 13, 2024
TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors.
Via
InvestorPlace
TransCode Therapeutics Open Letter to Shareholders
May 13, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Looking Into TransCode Therapeutics's Recent Short Interest
January 29, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
April 15, 2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
April 03, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28, 2024
Medical oncologist brings over 25 years of industry experience to lead Clinical Development Strategy
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
March 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
March 06, 2024
Highlights TTX-MC138’s Path from Target Discovery to the Clinic
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic
February 20, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
February 01, 2024
Shares of Nextracker Inc. (NASDAQ: NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected thi
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
February 01, 2024
It's time to get into the biggest pre-market stock movers as we check out all of the hottest news happening on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via
Benzinga
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
January 31, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29, 2024
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces Closing of $7.25 Million Public Offering
January 22, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 22, 2024
Via
Benzinga
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 19, 2024
Via
Benzinga
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
January 18, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO
January 12, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
January 11, 2024
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives
January 04, 2024
Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A First-in-Class Compound Designed to Treat Metastatic...
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138
December 12, 2023
TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium
December 05, 2023
From
TransCode Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.